1 day ago
Cipla Signs Exclusive Pact for Experimental Breast Cancer Drug
Cipla has made a deal to develop and sell an experimental cancer medicine.
The medicine is called TQB2102, or Rolditamig Deuderuxtecan.
It is designed to find HER2 proteins on cancer cells and deliver medicine to them.
Researchers are testing it in breast cancer and some other cancers.
Early results have shown promise in advanced breast cancer with low levels of HER2.
Cipla will test the drug and apply for approvals in several emerging markets.
The Chinese company that developed it will continue making and supplying it.
The treatment is not yet confirmed as approved for patients in these markets.
Cipla signed an exclusive licensing and supply agreement with Chia Tai Tianqing Pharmaceutical Group for TQB2102.
The agreement covers development and sales in India, South Africa and five other emerging markets.
TQB2102 is a HER2 bispecific antibody-drug conjugate being tested in several HER2-expressing cancers.
The drug has shown early promise in HER2-low advanced breast cancer and received three Breakthrough Therapy Designations in China.
Cipla will conduct trials, seek regulatory approvals and commercialise the drug, while CTTQ will manufacture and supply it.
- Who
- Cipla and Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical Limited.
- What
- They signed an exclusive licensing and supply agreement for the experimental breast cancer drug TQB2102, also called Rolditamig Deuderuxtecan.
- Where
- The licensed territories are India, South Africa and five other emerging markets; the drug was developed by CTTQ in China.
- When
- The agreement was announced in the company’s stock-exchange filing; the article also reports Cipla’s share performance as of September 1.
- Why
- To develop, obtain approvals for and commercialise a potential HER2-targeted cancer treatment in markets with unmet patient needs.
Key facts
- Drug
- TQB2102, also known as Rolditamig Deuderuxtecan
- Drug type
- HER2 bispecific antibody-drug conjugate
- Cipla responsibilities
- Local clinical trials, regulatory filings and commercialisation
- CTTQ responsibilities
- Manufacturing and supplying the drug
- Licensed markets
- India, South Africa and five other emerging markets
- Most advanced data
- HER2-low advanced breast cancer
- China designations
- Three Breakthrough Therapy Designations covering specified breast, colorectal and biliary tract cancers
Quotes
Achin Gupta
Managing director and global chief executive officer of Cipla
“At Cipla, innovation is central to our mission of expanding access to therapies that address unmet patient needs.”
financialexpress.com
Sources
Related news
India’s Smart Cancer Drug RK-251 Targets Tumor Cells
Indian Scientists Develop Smart Drug Targeting Aggressive Breast Cancer
Piramal, Anthem and Cohance Pursue Different ADC Bets
Mankind Pharma Signs China Deal for Two Insulin Products
Argentina Moves to Lower Barriers for Indian Pharma Trade
Nepal Plans New Landslide Warning System Along China Border
RBI Governor Meets US Fed Chief Kevin Warsh at G20
Tencent-Backed Enflame IPO Draws Massive Investor Demand
Falling Urea Prices Offer India Relief From Subsidy Pressure
Pentagon Turmoil Deepens as Hegseth Tightens Grip on Military
